Drug Search Results
More Filters [+]

AC-105

Alternative Names: ac-105, ac105, ac 105
Latest Update: 2020-12-18
Latest Update Note: News Article

Product Description

a propriety magnesium formulation being studied as a treatment for acute spinal cord injury (SCI)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Acorda
Company Location: ARDSLEY NY 10502
Company CEO: Ron Cohen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AC-105

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Spinal Cord Injuries

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AC105

P2

Terminated

Spinal Cord Injuries

2015-02-01

Recent News Events